References
- Kingsberg SA, Wysocki S, Magnus L, Krychman ML. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women’s VIews of Treatment Options for Menopausal Vaginal ChangEs) survey. J Sex Med 2013;10:1790–9
- Nachtigall LE, Nachtigall MJ. Hormone replacement therapy. Curr Opin Obstet Gynecol 1992;4:907–13
- Rahn DD, Carberry C, Sanses TV, et al. Vaginal estrogen for genitourinary syndrome of menopause: a systematic review. Obstet Gynecol 2014;124:1147–56
- Notelovitz M, Funk S, Nanavati N, Mazzeo M. Estradiol absorption from vaginal tablets in postmenopausal women. Obstet Gynecol 2002;99:556–62
- Bygdeman M, Swahn ML. Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas 1996;23:259–63
- Ghazanfarpour M, Latifnejad Roudsari R, Treglia G, Sadeghi R. Topical administration of isoflavones for treatment of vaginal symptoms in postmenopausal women: A systematic review of randomised controlled trials. J Obstet Gynaecol 2015 Aug 19. Epub ahead of print
- Barnes KN, Pearce EF, Yancey AM, Forinash AB. Ospemifene in the treatment of vulvovaginal atrophy. Ann Pharmacother 2014;48:752–7
- Archer DF. Dehydroepiandrosterone intra vaginal administration for the management of postmenopausal vulvovaginal atrophy. J Steroid Biochem Mol Biol 2015;145:139–43
- Perino A, Calligaro A, Forlani F, et al. Vulvo-vaginal atrophy: A new treatment modality using thermo-ablative fractional CO2 laser. Maturitas 2015;80:296–301
- Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause 2013;20:888–902
- Sturdee DW, Panay N; International Menopause Society Writing Group. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric 2010;13:509–22
- Utian WH, Maamari R. Attitudes and approaches to vaginal atrophy in postmenopausal women: a focus group qualitative study. Climacteric 2014;17:29–36
- Kingsberg SA, Krychman ML. Resistance and barriers to local estrogen therapy in women with atrophic vaginitis. J Sex Med 2013;10:1567–74
- http://www.novo-pi.com/vagifem.pdf
- http://labeling.pfizer.com/showlabeling.aspx?id = 132
- Archer DF, Labrie F, Bouchard C, et al. Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone). Menopause 2015;22:950–63
- Eugster-Hausmann M, Waitzinger J, Lehnick D, et al. Minimized estradiol absorption with ultra-low dose 10 μg 17β-estradiol vaginal tablets. Climacteric 2010;13:219–27
- Manson JE, et al.for the Working Group on Women's Health and Well-Being in Menopause. Why the product labeling for low-dose vaginal estrogen should be changed. Menopause 2014; 21:911–16
- http://www.menopause.org/docs/default-source/for-women/algorithm_for_patients_full-paper_rounded-logo-2014-10-10.pdf?sfvrsn = 2
- Takahashi TA, Johnson KM. Menopause. Med Clin North Am 2015;99:521–53